Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides

Sarcoidosis Vasculitis and Diffuse Lung Disease

Volumn 13, Issue 3, 1996, Pages 241-245

  Cohen Tervaert, Jan Willem ^a   Stegeman, Coen A ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA testing; Vasculitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G3; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE;

ANTIBODY TITER; ARTHRALGIA; CLINICAL TRIAL; DISEASE ACTIVITY; GLOMERULONEPHRITIS; HUMAN; LEUKOCYTE ACTIVATION; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; MONITORING, IMMUNOLOGIC; VASCULITIS;

EID: 0029743669     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (40)

1. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW: Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15.
2. Balow JE, Fauci AS: Vasculitic diseases of the kidney: polyarteritis, Wegener's granulomatosis, necrotizing and crescentic glomerulonephritis, and other disorders. In: Schrier RW, Gottschalk CW (ed.). Diseases of the kidney. 5th Edition. Little, Brown and Company, Boston; 1993: 2095-2117.
3. Gaskin G, Pusey CD: Systemic vasculitis. In: Cameron JS, Davison AM, Grünfeld J, Kerr DNS, Ritz E (eds.). Oxford textbook of clinical nephrology. Oxford University Press, Oxford; 1992: 612-636.
4. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH: Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-170.
5. Radis CD, Kahl LE, Baker GL et al: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995; 38: 1120-1127.
6. Kallenberg CGM, Brouwer E, Mulder AHL, Stegeman CA, Weening JJ, Cohen Tervaert JW: ANCA-pathophysiology revisited. Review. Clin Exp Immunol 1995; 100: 1-3.
7. Gross WL, Csernok E: Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol 1995; 7: 11-19.
8. Jennette JC, Falk RJ: Pathogenic potential of anti-neutrophil cytoplasmic antibodies. Lab Invest 1994; 70: 135-137.
9. van de Wiel A, Dolman KM, van der Meer-Gerritsen CH, Hack CE, von dem Borne AEGKr, Goldschmeding R: Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90: 409-114.
10. 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 1993; 93: 405-410.
11. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-4119.
12. Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41: 375-383.
13. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol 1992; 141: 335-342.
14. Charles LA, Caldas MLR, Falk RJ, Terrell RS, Jenette JC: Antibodies against granule proteins activate neutrophils in vitro. J Leukocyte Biol 1991; 50: 539-546.
15. Csernok E, Ernst M, Schmitt WH, Bainton DF, Gross WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-250.
16. Muller Kobold AC, Mesander G, Kallenberg CGM, Cohen Tervaert JW: Activated circulating neutrophils in relation to disease activity in ANCA-associated vasculitis (abstract). Clin Exp Immunol 1995; 101: 57.
17. Porges AJ, Redecha PB, Csernok E, Gross WL, Kimberly RP: Monoclonal ANCA (anti-MPO and anti-Pr3) engage and activate neutrophils via Fcτ Receptor IIA. J Immunol 1994; 153: 1271-1280.
18. Mulder AHL, Horst G, Limburg PC, Kallenberg CGM: Activation of neutrophils by antineutrophil cytoplasmic antibodies is FcR-depcndent. Clin Exp Immunol 1994; 98: 270-278.
19. Mayet WJ, Meyer zum Büschenfelde KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94: 440-446.
20. Mayet WJ, Schwarting A, Orth T, Duchman R, Meyer zum Büschenfelde KH: Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996; 103: 259-267.
21. Kobayashi K, Shibata T, Sugisaki T: Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995; 47: 454-463.
22. Brouwer E, Huitema MG, Klok PA, de Weerd H, Cohen Tervaert JW, Weening JJ, Kallenberg CGM: Anti-myeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med 1993; 177: 905-914.
23. Cohen Tervaert JW, van der Woude FJ, Fauci AS et al: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149: 2461-2465.
24. Stegeman CA, Cohen Tervaert JW, Sluiter WJ at al.: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Int Med 1994; 120: 12-17.
25. Stegeman CA, Cohen Tervaert JW, Mulder AHL et al: Levels of the IgG3 subclass of ANCA directed against proteinase 3 are related to disease activity in patients with Wegener's granulomatosis. In: Stegeman CA. Wegener's granulomatosis: immunological and microbiological factors involved in disease activation. PhD Thesis. University of Groningen, Groningen; 1995: 37-55.
26. Jayne DRW, Gaskin G, Puscy CD, Lockwood CM: ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88: 127-133.
27. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD: Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-389.
28. Cohen Tervaert JW, Huitema MG, Hene RJ et al: Prevention of relapses of Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711.
29. Specks U, Wheatley CL, McDonald TJ, Rohrbach MS, DeRemee RA: Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clin Proc 1989; 64: 28-36.
30. Egner W, Chapel HM: Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990; 82: 244-249.
31. Halma C, Daha MR, Schrama E, Hermans J, van Es LA, van der Woude FJ: Value of anti-neutrophil cytoplasmic autoantibodies and other laboratory parameters in follow-up of vasculitis. Scand J Rheumatology 1990; 19: 392-397.
32. Pettersson E, Heigl Z: Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37: 219-228.
33. Chan TM, Frampton G, Jayne DRW, Perry GJ, Lockwood CM, Cameron JS: Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993; 22: 387-392.
34. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS: Limited prognostic value of changes in antincutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-371.
35. Devenport A, Lock RJ, Wallington T: Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995; 15: 201-207.
36. Jayne DRW, Weetman AP, Lockwood CM: IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 1991; 84: 476-481.
37. Esnault VLM, Jayne DRW, Weetman AP, Lockwood CM: IgG subclass distribution and relative functional affinity of antimyeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. Immunology 1991; 74: 714-718.
38. Brouwer E, Cohen Tervaert JW, Horst G et al: Predominance of IgG1 and IgG4 subclass of antineutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991; 83: 379-386.
39. Cohen Tervaert JW, Mulder AHL, Kallenberg CGM, Stegeman CA: Measurement of IgG3 levels of anti-proteinase 3 antibodies is useful in monitoring disease activity in Wegener's granulomatosis (abstract). J Am Soc Nephrol 1994; 5: 828.
40. Mulder AHL, Stegeman CA, Kallenberg CGM: Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101: 227-232.